BeyondSpring says FDA granted fast track to plinabulin plus docetaxel in lung cancer; agrees to sell majority of China unit to Biolin

BeyondSpring said the FDA granted fast track designation to plinabulin plus docetaxel in lung cancer, and that it agreed to sell a majority stake in its China unit to Biolin, which will fund China Phase 3 enrollment.

Detected & updated continuously · Source: Nebula